Evrópusambandið - íslenska - EMA (European Medicines Agency)

diurnal europe b.v. - hýdrókortisón - skert nýrnastarfsemi - barksterar til almennrar notkunar - skipti meðferð skammta frekar í börn, börn og unglingar (frá fæðingu að < 18 ára).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mergæxli - Æxlishemjandi lyf - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

grünenthal gmbh* - testosterone - stungulyf, lausn - 1000 mg/ 4 ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - methotrexatum inn - tafla - 2,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,75 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

novartis healthcare a/s - everolimusum inn - tafla - 0,25 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

apofri ab - levonorgestrelum inn - tafla - 1,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

gedeon richter plc.* - progesteronum inn - leggangastíll - 400 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

pfizer aps - alprostadilum inn - stungulyfsstofn og leysir, lausn - 10 míkróg